Lipid Sciences, Inc. (NASDAQ: LIPD) today reported that it had received conditional approval for the Company’s Investigational Device Exemption (IDE) application from the Center for Devices and Radiological Health of the Food and Drug Administration (FDA) to begin a human clinical trial of the Company’s Plasma Delipidation System-2 (PDS-2). The Company filed this application with the FDA on December 29, 2005. Lipid Sciences has been granted this approval on the condition that within 45 days it will submit a response to the questions raised and observations made by the FDA. Lipid Sciences is also in the process of obtaining approval from the Institutional Review Board (IRB) of the Washington Hospital Center (WHC), Washington, D.C., for the Company’s human clinical trial and will submit that approval to the FDA.
